Chemotherapy drugs cyclophosphamide, cisplatin and doxorubicin induce germ cell loss in an in vitro model of the prepubertal testis

Ellie Smart1,3, Federica Lopes1, Siobhan Rice1,4, Boglarka Nagy1, Richard A. Anderson2, Rod T. Mitchell2 & Norah Spears1

Long term survival rates for childhood cancers is steadily increasing, however cancer survivors can experience fertility problems as a consequence of chemotherapy treatment. This is particularly problematic for young boys, for whom no fertility preservation treatment is yet established. Here, we have determined the effects on prepubertal mouse testis of three commonly used chemotherapy drugs; cyclophosphamide (using its active metabolite phosphoramide mustard), cisplatin and doxorubicin, exposing testicular fragments to a clinically relevant range of concentrations in vitro. All three drugs induced a specific and highly significant loss of germ cells, including spermatogonial stem cells. In contrast, there was no significant effect on somatic cells, for either Sertoli or interstitial cells. Time course analysis of cleaved Caspase-3 expression showed a significant increase in apoptosis eight hours prior to a detectable decrease in germ cell numbers following exposure to phosphoramide mustard or cisplatin, although this pattern was not seen following doxorubicin-exposure. Moreover, analysis of DNA damage at 16 h showed increased γH2AX expression in response to all three drugs. Overall, results show that cisplatin, doxorubicin and cyclophosphamide all specifically induce loss of germ cells, including of spermatogonial stem cells, in the prepubertal mouse testis at concentrations relevant to human therapeutic exposures.

Survival rates from most childhood cancers have increased dramatically over recent decades, with chemotherapy a mainstay of treatment for the majority of these patients. Ideally, chemotherapeutic agents would specifically target cancerous cells without affecting healthy tissue, however in practice there are many off-target effects of cytotoxic treatments, including on the gonads. There is now a growing population of cancer survivors suffering from chemotherapy-induced infertility with some also affected by hypogonadism, effects that can significantly impact on quality of life. The situation is of particular concern for male childhood cancer patients due to the lack of fertility preservation methods available for prepubertal males.

Prepuberty in humans can be defined as the period from late infancy until the onset of puberty: during this period there is relatively little testicular activity, with low rates of proliferation within the spermatogonial germ cell and Sertoli cell populations compared to the frequent proliferation that occurs in these cells during infancy and adulthood2,3. Although occasional germ cells enter meiosis during prepuberty, these cells subsequently undergo apoptosis4. Of particular importance during the prepubertal period is the quiescence of the HPG axis with very low levels of gonadotrophins and testosterone2,3,5. The comparative quiescence of the prepubertal testis was once thought to confer protection from chemotherapy-induced damage6. However, males treated before

1Biomedical Sciences, University of Edinburgh, Edinburgh, EH8 9XD, United Kingdom. 2MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, EH16 4TJ, United Kingdom. 3Present address: Center for Dermatology Research, University of Manchester, Manchester, United Kingdom. 4Present address: Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, University of Oxford, Oxford, OX3 9DS, United Kingdom. Ellie Smart and Federica Lopes contributed equally to this work. Rod T. Mitchell and Norah Spears jointly supervised this work. Correspondence and requests for materials should be addressed to N.S. (email: norah.spears@ed.ac.uk)
puberty may present in adulthood with oligo- or azoospermia, with the extent of damage to the seminiferous epithelium related to both drug regimen and cumulative dose received. Such damage might be related to the activity that takes place in the prepubertal testis, such as Sertoli cell maturation or germ cell proliferation. Despite the clear evidence that chemotherapy drug exposure to prepubertal boys can affect subsequent fertility, there is little information as to how these drugs damage the prepubertal testis. Given that the prepubertal testis tissue, germ cell stages and hormonal environment is markedly different from that of the pubertal or adult testis, it cannot be assumed that drug effects will be similar at both stages. Thus, a fuller understanding of how germ cells in the prepubertal testis are lost or damaged by specific chemotherapy drugs is vital for the provision of accurate advice and for the development of preventative treatments to protect fertility in these patients. It is also important to determine effects of these drugs specifically on the stem germ cell population, since survival of a sufficient number of spermatogonial stem cells (SSCs) allows for the possibility of subsequent germ cell repopulation of the testis, with the potential to restore fertility.

Here, we examine the individual effects of three different chemotherapeutic agents: cyclophosphamide (CYP); cisplatin (CIS); and doxorubicin (DOX). These three drugs were chosen as they are all commonly used in the treatment of a range of prepuberty cancers, thus with more clinical information available, including that of patient serum concentrations. CYP is an alkylating agent that is metabolised in the liver to a number of compounds, the most active of which is phosphoramid mustard (PM). PM binds an alkyl molecule to DNA, forming an adduct that prevents DNA replication. It is widely believed that alkylating agents are the most gonadotoxic chemotherapy drugs, and that the degree of gonadal damage can be related to the dose of alkylating agent received. CIS is one of several platinum-based chemotherapy drugs, all considered to act in an alkylating-like manner, but in which it is the platinum core that binds to DNA to form the adducts. The action of the anthracycline DOX is somewhat different, as it intercalates with DNA, inhibiting Topoisomerase II and hence preventing replication. DOX is often considered to be the least gonadotoxic of the agents examined here, only causing prolonged azoosperma when combined with other drugs.

We aimed to determine the effects of exposure to each of PM, CIS or DOX on prepubertal testis within a clinically-relevant range of concentrations. We utilised an in vitro culture system of prepubertal mouse testis tissue which we have previously demonstrated to support short-term development of the prepubertal mouse testis. This stage of development in rodents has important similarities to the human during prepuberty in terms of relative quiescence of the hypothalamic-pituitary-gonadal (HPG) axis and the presence of a germ cell population consisting almost exclusively of spermatogonia. However, when determining potential relevance to humans there are also key species differences that should be considered such as the precise spermatogonial sub-populations and rates of Sertoli cell proliferation. Using this system we were able to examine the direct effects of each drug, and to provide a comparison of relative gonadotoxicity between drugs. Exposure to each of the three chemotherapeutic agents resulted in a significant reduction in germ cell number, which include the promyelocytic leukemia zinc-finger-positive (PLZF-) SSC sub-population.

Results
Cyclophosphamide, cisplatin and doxorubicin each result in a specific loss of germ cells. Both Control testis and tissue exposed to PM, CIS or DOX had morphologically normal tubules, with basement membrane separating tubules from interstitium (Fig. 1). Control cultured testis was healthy, with germ cells situated along the basement membrane of the seminiferous tubules. After exposure to Low concentrations of PM, CIS or DOX, germ cells could still be observed either at the basement membrane or in the centre of the tubules (Fig. 1B); in contrast, it was difficult to identify germ cells after exposure to High concentrations of any of the three drugs, after which pyknotic cells were clearly visible and the majority of tubules appeared to contain only Sertoli cells (Fig. 1C). Seminiferous tubule diameter decreased in response to Mid (p < 0.01) or High (p < 0.001) levels of CIS or DOX, although no decrease was found after exposure to PM (Fig. 1A). Seminiferous tubules containing only Sertoli cells were found in less than 10% of Control cultured tubules, but these Sertoli cell-only tubules increased markedly in response to all three drugs, until over 95% of tubules lacked germ cells after exposure to the High drug concentrations, no Mvh+ cells remaining; Low CIS 40-fold difference; Mid/High CIS 500-to 1000-fold difference; Low and Mid DOX 50-fold difference; and High DOX 100-fold difference. The majority of germ cells were seen to be proliferating (Mvh+/BrdU+), other than where the germ cell population had been reduced by 100-fold or more, where few if any proliferating germ cells remained (Fig. 1D).

Expression of mouse vasa homologue (Mvh) was used to identify germ cells using immunohistochemistry (IHC), with seminiferous tubules of Control tissue lined by germ cells, many of which were proliferative, as shown by incorporation of bromo-2'-deoxyuridine (BrdU; Fig. 2A). In response to exposure to any of the three chemotherapeutic agents, there was a marked loss of germ cells from the seminiferous tubules (Fig. 3B). Proliferating Mvh+/BrdU+ germ cells were still seen after exposure to the Low concentration of each drug, even amongst the sub-populations and rates of Sertoli cell proliferation. Using this system we were able to examine the direct effects of each drug, and to provide a comparison of relative gonadotoxicity between drugs. Exposure to each of the three chemotherapeutic agents resulted in a significant reduction in germ cell number, which include the promyelocytic leukemia zinc-finger-positive (PLZF-) SSC sub-population.
PM compared to Low CIS or Low DOX exposure (Fig. 3). As with Mvh+ cells, few PLZF+ SSCs remained after exposure to PM, with only occasional SSC cells remaining after exposure to CIS or DOX (Fig. 4).

Somatic cell density is unaffected by cyclophosphamide, cisplatin or doxorubicin. Somatic Sertoli and interstitial cells were examined to see if they were also affected by any of the chemotherapy drugs. In contrast to the loss of germ cells, Sox9+ Sertoli cells were found lining the seminiferous tubules in all High drug-exposed tissues, as in Controls (Fig. 5A–D). Quantification of expression area showed no significant effect on the proportion of the tubules occupied by Sertoli cells on exposure to any of the drugs, even at High concentrations (Fig. 5E: (i) PM p = 0.54; (ii) CIS p = 0.63; (iii) DOX p = 0.93), with expression area shown to correlate closely with manual cell counts (p < 0.0001; Supplementary Figure S2). There is some Sertoli cell proliferation during early postnatal development and small numbers of Sox9+/BrdU+ proliferating Sertoli cells were seen in Control cultures (Fig. 5A inset) and in all treatment groups, even after exposure to High concentrations of each of the three drugs (Fig. 5B–D insets).

Interstitial cells were examined by determining expression of chicken ovalbumin upstream promoter transcription factor II (COUPTFII), expressed in the majority of interstitial cells in the neonatal mouse including the cells that will differentiate into adult Leydig stem cells17. The interstitium contained mainly COUPTFII+ cells, both in the Control cultured testis and after exposure to each of the chemotherapy drugs, even at High

Figure 1. Effect of exposure to phosphoramide mustard, cisplatin or doxorubicin on tissue morphology. Representative photomicrographs of cultured testis fragments stained with haematoxylin and eosin. (A) Control tissue, or after exposure to (B) Low or (C) High concentrations of (i) PM, (ii) CIS or (iii) DOX. Arrows indicate germ cells. Scale bars represent 100 µm; scale bars in insets represent 20 µm.
concentrations (Fig. 6A–D). Quantification of expression showed no effect of any drug on the percentage of the interstitial area containing COUPTFII+ interstitial cells (Fig. 6E: (i) PM p = 0.55; (ii) CIS p = 0.88; (iii) DOX p = 0.15).

Increase in apoptosis and DNA damage in response to exposure to cyclophosphamide, cisplatin or doxorubicin. Apoptosis was examined using IHC for cleaved-Caspase-3 (CC3). At the end of the culture period, two days after exposure to the chemotherapy drugs had ended, there was relatively little expression of CC3 in testis exposed to Low concentrations of any of the three drugs (Fig. 6A–D). However, quantification of expression within seminiferous tubules showed a significant increase in apoptosis of around 5- to 6-fold after exposure to High CIS (p < 0.001) or to Mid or High DOX concentrations (p < 0.01 and 0.001 respectively; Fig. 6F). PM-treated tissue did not show significantly different levels of CC3 to Control at any concentration.

Given that an increase in apoptosis might occur only as a more immediate response to the chemotherapy drugs, a time course analysis was undertaken. Testis fragments were cultured for 24 h in control medium, and then exposed to Mid PM, Low CIS or Low DOX: the Mid PM concentration was used due to the markedly higher survival of germ cells after Low PM compared to Low CIS or Low DOX exposure (Fig. 3). As in earlier experiments, drug exposure was for up to 24 h, after which tissue was moved back into drug-free medium. Tissue was removed from culture at 8 h intervals, for up to 40 h after the start of drug exposure. IHC was carried out to determine the level of apoptosis (CC3), and the number of germ cells (Mvh expression). Each of the three chemotherapy drugs induced a distinct pattern of response (Fig. 7): PM resulted in a significant increase in the amount of CC3 16 h after drug-exposure (p < 0.01) followed by a significant decrease in Mvh expression 8 h later, at the 24 h time point (p < 0.01); CIS resulted in a significant increase in the amount of CC3 after 24 h (p < 0.01) followed by a significant decrease in Mvh expression 8 h later, at the 32 h time point (p < 0.05); in contrast, there was no significant effect on CC3 at any time after DOX exposure. Here, Mvh expression was significantly decreased only at the 40 h time point (p < 0.001), but this decrease was not preceded by an increase in the amount of CC3. In case there was a shorter interval between an increase in the amount of CC3 and germ cell loss compared to the other drugs, levels of CC3 at 36 h following DOX-exposure was also investigated: no significant increase in CC3 was found at this time point, with the percentage of seminiferous tubule positive for CC3 as follows: mean ± sem of Control 0.12 ± 0.02 (n = 8) and DOX-exposed 0.21 ± 0.06 (n = 5); p = 0.14.

Figure 2. Exposure to phosphoramide mustard, cisplatin or doxorubicin results in smaller, and Sertoli cell-only seminiferous tubules. (A) Seminiferous tubule diameter; n = 8 for all conditions except high PM where n = 7. (B) Percentage of seminiferous tubules that contain only Sertoli cells: (Bi) PM; n = 6–17, (Bii) CIS; n = 5–8, (Biii) DOX; n = 11–17. Data are mean ± SEM; p < 0.01 (**), p < 0.001 (***)) for treatment versus Control.
DNA damage was then investigated by carrying out IHC for phosphorylated, γH2AX, analysing only the high intensity foci that occur in response to germ cell damage 18–20. Preliminary experiments showed no significant change in γH2AX expression eight hours after the start of drug exposure (see Supplementary data S1), so tissue was then examined 16 h after exposure to PM, CIS or DOX (Fig. 8). Here, damage was evident after exposure to all three drugs (PM p < 0.05; CIS and DOX p < 0.01).

Proliferation within seminiferous tubules is decreased on exposure to cisplatin or doxorubicin but not phosphoramide mustard. BrdU was added to the medium for the final 24 h of culture in order to examine the proliferative capacity of the tissue following exposure to chemotherapeutics. BrdU incorporation
µ to produce concentrations of 0.05 (Low), 0.1 (Mid) or 0.5 (High) g ml

seminiferous tubule after exposure to Mid PM, Low CIS or Low DOX; n are mean

previously found in patient serum 22,23. Tissue was exposed to CIS at 0.1 (Low), 0.5 (Mid) or 1 (High)

fully functional spermatogenesis9,21. These male childhood cancer patients are particularly important to consider,

It has long been recognised that chemotherapy treatment can have adverse effects on male reproduction, includ-

Discussion
It has long been recognised that chemotherapy treatment can have adverse effects on male reproduction, includ-

decreased significantly after exposure to all concentrations of CIS (2-fold; p < 0.001 in each case) or DOX (2-fold

reduction in response to Low or Mid DOX and 6- to 7-fold reduction in response to High DOX; p < 0.001 in
each case): in contrast, there was no significant change in BrdU incorporation following PM exposure (p = 0.14;
Fig. 9A). Separate examination of proliferation within the tubule (Fig. 9B) and interstitial (Fig. 9C) areas showed
that the difference in proliferation in response to CIS or DOX exposure was primarily due to effects within the
tubule, while there was no significant effect of CIS or DOX in the interstitium other than in the High DOX treat-
ment group, which exhibited a 3.5-fold decrease in expression (p < 0.01). As with proliferation in the tissue as a
whole, there was no effect of PM on proliferation within either the tubule or the interstitium.

Figure 4. Exposure to phosphoramide mustard, cisplatin or doxorubicin results in loss of spermatogonial
stem cells (SSCs). (A,B) Representative photomicrographs of cultured testis fragments from (A) Control
and (B) treated (PM), with immunohistochemical localization of PLZF (green) to identify SSCs, and of Mvh
(red) to identify all germ cells; sections are counterstained with DAPI (blue). White arrows indicate PLZF+/Mvh− SSCs; yellow arrow indicates PLZF−/Mvh+ non-SSC germ cells. (C) Number of PLZF+ SSCs per mm2 of
seminiferous tubule after exposure to Mid PM, Low CIS or Low DOX; n = 4–8. Scale bars represent 25 µm. Data
are mean ± SEM; p < 0.05 (*), p < 0.01 (***) for treatment versus Control.

dramatic loss of germ cells when administered at clinically relevant concentrations, with little effect evident on
the somatic cell component of the testis.

Culture medium was supplemented with PM, CIS or DOX, with effects of each drug determined across the
range of concentrations that have been reported in patient serum. PM concentrations used were 0.02 (Low), 0.2
(Mid) or 2 (High) µg ml−1, equivalent to roughly 0.1 (Low), 1.0 (Mid) or 10 (High) µM, with from 0.1 to 10 µM
previously found in patient serum.22,23. Tissue was exposed to CIS at 0.1 (Low), 0.5 (Mid) or 1 (High) µg ml−1,
with reported patient serum concentrations from 0.4 to 1 µg ml−1.24,25. Finally, DOX was added to culture medium
to produce concentrations of 0.05 (Low), 0.1 (Mid) or 0.5 (High) µg ml−1, with reports of 0.01 to 0.6 µg ml−1 in
patient serum.13,28. Whilst it is not possible to determine the concentrations of these drugs that occur within tes-
ticular tissue in vivo, these experiments here do allow comparison of the gonadotoxicity of the different drugs at
concentrations relative to their circulating levels in patients.

The majority of work examining the effects of chemotherapy drugs on gonadal function in rodents have
looked at the post-pubertal testis, with exposure to CYP, CIS and DOX all resulting in germ cell damage [for example27–31]. However, the adult testis, with fully functional spermatogenesis, is a very different, and more active
cellular environment than the prepubertal testis, and there is no evidence that results obtained on the former
tissue can be directly applied to the latter. In contrast to the more extensive literature on adult testis, few reports
have been published on the effects of chemotherapy drugs on the prepubertal testis. This is despite the fact that
prepubertal boys cannot yet be offered any fertility preservation method that has been shown to be successful in
humans, with potential techniques such as testicular tissue transplantation or in vitro development of spermatoo-
za from spermatogonia currently achieved only in animal models32,33.
Results here showed that exposure to the Low concentration of PM, the active metabolite of CYP, had less of an effect on germ cell numbers than exposure to Low CIS or DOX (1.5 fold compared to 40- and 50-fold respectively), perhaps a surprising result given that the clinical literature indicates that treatment with alkylating agents in general, and cyclophosphamide in particular, has the strongest association with fertility problems in males. However, for all three drugs, few germ cells remained after exposure to Mid or High concentrations. There has been little investigation into the effect of CYP on the prepubertal testis, with no effect reported after in vivo exposure of prepubertal rats, while the testes of prepubertal mice who were administered CYP were not examined until after puberty. To the best of the authors' knowledge, there are no publications on laboratory investigations into the effects of CIS on the prepubertal testis. Finally, while DOX has previously been considered to be less gonadotoxic than CYP or CIS, the gonadotoxic effects of DOX found on germ cells here are consistent with those in prepubertal rats in vivo, and to a study in a prepubertal rat in vitro model using similar concentrations of DOX.

The potential for germ cell repopulation of the seminiferous tubules after chemotherapy-induced loss will depend on the survival of proliferative germ cells, specifically those spermatogonia that are stem cells. SSCs are necessary both for self-renewal of the germ stem cell population and also for the cellular divisions that support the differentiation leading to complete spermatogenesis. A small number of Mvh+/BrdU+ proliferating germ cells did remain after Low CIS exposure, but importantly, PLZF-expressing SSCs were rarely seen after exposure to Low CIS concentrations. Damage induced by DOX-exposure was at least equivalent to CIS, with PLZF+ SSCs...
rarely seen even following exposure to Low DOX concentrations, while after exposure to High DOX, no BrdU\(^+\) proliferative germ cells remained. The situation after PM exposure was more complex: there was less effect on the germ cell population as a whole after exposure to lower concentrations, and more PLZF\(^+\) SSCs remained after Mid PM exposure, but in contrast, High PM exposure was the only treatment group in which no germ cells were found. Bearing in mind that experiments here used a short-term in vitro mouse model, our results highlight the importance of further work in this area, to directly determine whether SSCs are able to repopulate the seminiferous tubules following chemotherapy drug-induced damage, perhaps along with work using human tissue or non-human primate models. Overall, results here indicate that the longer term consequences of treatment with

---

**Figure 6.** Apoptosis is increased, but interstitial cell density unaffected, by exposure to phosphoramidemustard, cisplatin or doxorubicin. (A–D) Representative photomicrographs of cultured testis fragments showing immunohistochemical localisation of COUPTFII (red) and CC3 (green), counterstained with DAPI (blue). (A) Control cultured testis shows COUPTFII expression in the majority of interstitial cells, with little evidence of apoptosis (CC3-expression). (B–D) Tissue from High concentration of each of: (B) PM, (C) CIS or (D) DOX shows similar COUPTFII expression pattern, alongside increasing evidence of apoptosis (CC3\(^+\) cells). (E) Percentage of interstitium positive for COUPTFII after exposure to increasing concentrations of: (Ei) PM, (Eii) CIS or (Eiii) DOX. (F) Percentage of seminiferous tubules positive for CC3 after exposure to increasing concentrations of: (Fi) PM, (Fii) CIS or (Fiii) DOX. E,F: n = 8 for all groups except High PM, where n = 7. Scale bars represent 50\(\mu\)m. Data are mean + SEM; p < 0.01 (**), p < 0.001 (***) for treatment versus Control.
CYP are more pronounced at higher concentrations, and that DOX may be as, or even more damaging than CIS, with both of these drugs already inducing marked damage at relatively low concentrations. The effects of CYP and CIS tie in with clinical findings, but DOX has been considered to have more limited fertility consequences. This could reflect the difficulty in determining the gonadotoxicity of individual drugs from clinical studies in which patients are treated with complex drug-combinations.

Whilst the present study clearly demonstrate a loss of spermatogonia in the prepubertal rodent testis following exposure to chemotherapeutics, including in the PLZF+ SSC population, there are a number of important considerations when extrapolating these findings to human. Similarities between the postnatal day 5 (pnd5) mouse and prepubertal human include the fact that the HPG axis is quiescent during this period of development and therefore there is no impact of gonadotrophins or of testosterone within the testis. Whilst in both species, the germ cell population consists almost exclusively of spermatogonia, the spermatogonial sub-populations differ. Importantly, in rodents, the A single spermatogonia can perform a dual function by acting either as stem cell or progenitor, whilst in the human these functions are performed by the A dark and A pale spermatogonial populations respectively. As such, it is important to bear in mind that this could result in differences in sensitivity to chemotherapeutics and also in the potential for subsequent recovery. Another important consideration regarding species differences in germ cells during this period of development is the rate of spermatogonial proliferation. Whilst in rodents there is a relatively high proliferation at pnd5, as demonstrated in the present study, the rate of prepubertal spermatogonial proliferation in humans and non-human primates is relatively low in comparison. This is of particular relevance in relation to chemotherapy exposures, which often target mitotically active cells.

At the end of the four day culture period, 48 h after the drug exposure period had ended, there was little evidence of apoptosis, with significant increases in CC3 expression seen only after exposure to High CIS, or to Mid or High DOX, and with no significant increase found after PM exposure. Apoptosis was therefore examined in a time-course analysis at 8-h intervals following exposure to each drug, with results showing a difference in the response of the prepubertal testis to each of the three drugs. After exposure to PM or CIS, there was a similar pattern of a significant increase in apoptosis followed eight hours later by a significant decrease in germ cells, although the precise timing of this response differed between the two drugs, occurring earlier following exposure to PM than to CIS. In contrast, no significant increase in CC3 was seen at any time point after DOX-exposure, despite the significant decrease in germ cells first seen 40 h after the start of drug-exposure. The lack of a significant increase in CC3-expression in response to DOX could have been because increased expression occurred within the 8 h interval of the time course analysis; however, there was also no effect on CC3 expression midway through the time interval immediately before the significant effect on germ cells, 36 h after the start of DOX-exposure. Given the lack of any increase in CC3 expression in response to DOX exposure, DNA damage was investigated by examining expression of phosphorylated H2AX. Phosphorylation of H2AX is one of the earliest responses to double stranded DNA breaks (DSBs), with immunofluorescence analysis of ‘γH2AX showing the presence of discrete foci in cell nuclei that have undergone DSBs. The analysis here investigated only the intense foci of expression that are an indicator of germ cell DNA damage, due to the occurrence of low intensity foci in healthy male germ cells. Results showed a significant, marked increase in such foci in response to all three drugs after 16 h, with DOX exposure leading to the largest increase: CYP and CIS have previously been shown to
Figure 8. Exposure to phosphoramidate mustard, cisplatin or doxorubicin leads to increased expression of phosphorylated H2AX. Representative photomicrographs of cultured testis fragments showing immunohistochemical localisation of γH2AX (green) of cultured testis tissue collected 16 h after the start of drug exposure, counterstained with DAPI (blue). (A) Analysis of γH2AX expression using ImageJ/Fiji software. (Ai) Photomicrograph showing cells with high intensity foci (arrow) and with low intensity foci (arrowhead) of γH2AX. (Aii) Black and white image of selected areas containing only cells with high intensity foci (arrow), after setting a high intensity threshold to exclude cells with low intensity foci (arrowhead) alongside a minimum particle size to exclude signals too small to be cells. (Aiii) Image showing the selected areas (black areas in Aii) from which pixel intensity is measured to obtain value of integrated density. (B–E) Representative images showing γH2AX expression from each group; (B) Control, (C) Mid PM, (D) Low CIS, (E) Low DOX. (F) Intensity of γH2AX expression normalised for tubule area; n = 6 in all groups. Scale bars represent 50µm. Data are mean ± SEM; p < 0.05 (*), p < 0.001 (***).
result in an increase in γH2AX in a mouse spermatogonial cell line. It remains to be seen if the DNA damage resulting from DOX exposure leads to apoptosis; or whether the germ cell loss may be the result of a different cell death pathway: DOX-induced cardiotoxicity has been shown to result in autophagy, with senescence reported in cell lines.

Despite the marked loss of germ cells, no significant effect was found on either Sertoli (area of Sox9 expression) or interstitial (area of COUPTFII expression) cell density. It is possible that more subtle damage has been induced in either/both somatic cell population(s), the effects of which would not become apparent until later. Downstream effects on the somatic cell population of the testis would be expected following germ cell loss: for example, absence of germ cells has been shown to alter Sertoli cell gene expression, the effects of which would not become apparent until later.

Effects of the chemotherapy drugs on proliferation rate in the somatic populations was determined by adding BrdU into the culture medium during the last 24 h of culture. There was no effect on proliferation of interstitial cells following exposure to any of the drugs (except High DOX). However, there was a highly significant and marked decrease in BrdU+ cells within the seminiferous tubules in response to even Low concentrations of CIS or DOX, while no such effect was found in response to PM exposure. Given the relatively low rate of proliferation and stable density of Sertoli cells in Controls at this stage, the reduction in proliferation is likely to reflect the loss of proliferating germ cells. In the human, Sertoli cell proliferation occurs only during the neonatal period and...
following puberty, in contrast to the low level of proliferation that occurs throughout pre-puberty in the mouse. Findings here are in contrast with the effect of irradiation on the somatic compartment, which leads to a reduction in number of Sertoli cells and increase in apoptosis. Moreover, further studies are advisable in order to assess whether the production of key growth factors and other cytokines are affected by chemotherapy exposure, as shown after irradiation.

In summary, the work here, using an in vitro model of the mouse prepubertal testis, shows that the three chemotherapy drugs CYP (through use of its active metabolite PM), CIS and DOX each induced a rapid and marked decrease in the germ cell population after exposure to clinically relevant concentrations, and that this includes a decrease in the stem germ cell population. CIS and DOX exposure led to a marked drop in germ cell numbers even at the lower range of concentrations found in patient serum, while the effect of PM was less pronounced until higher concentrations were used, although High PM was the only treatment that led to a complete disappearance of germ cells. The total loss of germ cells in response to High PM alongside the near-disappearance of PLZF+ SSCs after exposure to Low concentrations of CIS or DOX, indicate that all three drugs may produce long-term reproductive damage. While the effects of CYP/PM and CIS are consistent with effects on fertility described in the clinical literature, results here indicate that DOX may have a similar level of gonadotoxicity as CYP and CIS. This work used prepubertal mouse testis as the experimental model, and whilst differences between rodent and primate testicular development during this period prevent direct translation of the findings into human, the present study has identified potentially important information on the effects of chemotherapy exposures that may be used to inform targeted studies in the prepubertal human or non-human primate testis, for which tissue is scarce and experimental models are currently lacking.

Methods

Animals. All work was approved by the University of Edinburgh’s Local Ethical Review Committee and carried out in accordance with UK home office regulations. C57Bl/J6 mice were housed in a 14 h light:10 h dark photoperiod, with access to food and water ad libitum.

Tissue Culture. Testis tissue was cultured as in Lopes and co-authors. Testes from a minimum of two pnd5 mice per culture run were dissected into Leibovitz L-15 dissection medium (Invitrogen, UK) supplemented with 3 mg ml⁻¹ bovine serum albumin (BSA; Sigma-Aldrich Ltd, UK) at 37 °C and then further dissected into pieces of approximately 0.5 mm³. Each piece of testis was transferred onto Whatman Nucleopore membrane (Camlab Ltd, UK) floating on 1 ml of α-MEM medium (Invitrogen, UK) supplemented with 10% Knockout Replacement Serum (Invitrogen, UK), within a 24-well plate (Greiner Bio-one, UK), and incubated at 37 °C, 5% CO₂. Cultures were left for 24 h (Day 1).

On Day 2 of culture, medium was supplemented with PM (Niomech, Germany), CIS (Sigma Aldrich, UK) or DOX (Sigma Aldrich, UK), with three concentrations per drug chosen to cover the range of reported serum levels in patients [PM: 0.02 µg ml⁻¹ (Low PM), 0.2 µg ml⁻¹ (Mid PM), or 2 µg ml⁻¹ (High PM); CIS: 0.1 µg ml⁻¹ (Low CIS), 0.5 µg ml⁻¹ (Mid CIS) or 1 µg ml⁻¹ (High CIS); and DOX: 0.05 µg ml⁻¹ (Low DOX), 0.1 µg ml⁻¹ (Mid DOX) or 0.5 µg ml⁻¹ (High DOX)] respectively. Due to its volatility, cultures containing PM were placed in separate culture plates and kept apart from other plates in the incubator. On Day 3 of culture, membranes were transferred into fresh control medium. On the final day of culture (Day 4), medium was additionally supplemented with 15 µg ml⁻¹ 5-BrDU (Sigma Aldrich Ltd, UK) for subsequent determination of cell proliferation. Twenty-four hours later, tissues were fixed for 90 mins in 10% neutral buffered formalin solution (Sigma Aldrich Ltd, UK) for IHC or for 60 mins in Bouin's fluid for histological examination, set in 3% agar (Sigma Aldrich Ltd, UK) and embedded in paraffin wax. For each drug, a minimum of 7 testis fragments from each concentration were examined, obtained from 2–3 culture runs.

For examination of spermatogonial stem cells (SSC), and for the time-course analysis, tissue was cultured either in control medium or exposed to the lowest drug concentration that earlier experiments had shown to result in a significant germ cell loss, namely Mid PM, Low CIS or Low DOX (Fig. 3). PLZF (marker of SSC) expression was examined after the four day culture period, as above. For the time-course analysis, tissue was removed from culture at eight-hourly intervals following the start of drug administration, and then processed as above. For each time point, 4–9 testis fragments were analysed, taken from a minimum of 2 culture runs, with specific sample sizes as follows: 8 hours - n=4–5; 16 hours - n=5–7; 24 hours - n=5–7; 32 hours - n=6–9; 40 hours - n=5–8. Gamma-H2AX (marker of double-strand DNA breaks) expression was examined after 16 hours only; n=6 for all.

Histology. Wax blocks were sectioned at 5 µm, and either taken for IHC (see below) or photomicrographs taken of haematoxylin and eosin-stained sections (DMLB Leica microscope, Leica Microsystems Ltd, UK) and used for morphological examination by a blind-to-treatment assessor using ImageJ software. In each section, the number of seminiferous tubules that lacked visible germ cells on the basement membrane (Sertoli cell-only tubules) was noted, and the diameter of every spherical tubule was measured.

Immunohistochemistry. IHC reactions were performed on one section from each of the testis fragment. Washes in phosphate-buffered saline (Fisher Scientific UK Ltd, UK) with 0.1% Triton X (PBSTx) were performed between each step. Antigen retrieval was performed in 0.01 M citrate buffer (pH6, Sigma Aldrich Ltd, UK), followed by blocking step with 20% normal goat serum diluted in PBSTx and 5% w/v BSA for 1 h at RT. Slides were incubated with primary antibodies (Table 1) overnight at 4 °C in a humidified environment followed by incubation with appropriate secondary antibody and visualisation reagent all at 1:200 dilution (Table 1):
specificities of expression patterns were tested by omission of primary or secondary antibodies. Details of all double IHCs are given in Table 2. Counterstaining was with 4,6-Diamidino-2-phenylindole (DAPI; Invitrogen, UK) at 1:5000 for 10 min and slides were then mounted with Vectashield hard-set mounting medium (Vector Laboratories, USA).

Image Acquisition and Analysis. Images were taken using a Leica DM5500B microscope with a DFC360FX camera. Image analysis was performed using ImageJ, with the assessor blind to treatment. For analysis of germ cells and proliferating germ cells, Mvh\(^+\)/BrdU\(^-\), Mvh\(^+\)/BrdU\(^+\) cells and PLZF\(^+\) cells were counted manually. For all other antibodies excepting \(\gamma\)H2AX, each fluorophore area assessed was measured as a percent- age of the section, tubule or interstitial area, as appropriate: this semi-automated system was verified by comparison with manual cell counting (Supplementary Figure 2), similar to results shown previously. Analysis of phosphorylated H2AX expression examined cells with high intensity expression only (Fig. 8A), due to the appearance of low intensity \(\gamma\)H2AX foci in healthy male germ cells, in contrast to the high intensity foci seen in damaged male germ cells.

From an initial image showing cells with low and high intensity foci (Fig. 8Ai), a high threshold was set in order to analyse only the cells with high intensity foci, alongside setting a minimum particle size to exclude any signal too small to be a cell. By calculating the intensity values of the pixels only in those areas selected in the grayscale image (Fig. 8Aii), the integrated density of \(\gamma\)H2AX expression was determined (Fig. 8Aiii), with results then normalized for tubule area.

Statistical analysis. For all analyses other than that of the time-course experiment, Minitab software was used. Statistical significance of treatment was determined using one-way ANOVA with a general linear mixed effect model to take culture run into account. This was followed by Dunnett's multiple comparisons to compare effects of different concentrations with Control. Data from the time-course study were analysed using GraphPad Prism. Here, for normally distributed data, one-way ANOVA was performed followed by Dunnett's post hoc test to determine statistical significance between Control and different drug concentrations; for data that were not normally distributed, Kruskal-Wallis was performed followed by Dunn’s post hoc test to determine statistical significance between Control and different drug concentrations. All results are given as mean ± SEM, with results considered statistically significant where \(p < 0.05\).

Data availability. All datasets generated and analysed during the current study are available: datasets used for specific figures are in Supplementary data S1; other datasets are available from the corresponding author on reasonable request.

---

**Table 1.** Antibodies and conditions for immunohistochemistry. Abbreviations: GAM-488: Alexafluor Goat anti-mouse IgG 488 nm. GAM-568: Alexafluor Goat anti-mouse IgG\(_5\) 568 nm. GARat-594: Alexafluor Goat anti-rat IgG\(_5\) 594 nm. GARE88: Alexafluor Goat anti-rabbit IgG 488 nm. GAR-b: Goat anti-rabbit biotinylated. GARat-b: Goat anti-rat biotinylated. Companies: 1Abcam, UK; 2Cell Signalling Technology, USA; 3R&D systems, USA; 4Millipore, UK; 5Vector Laboratories, USA; 6Invitrogen, UK; 7Life Technologies, UK; 8Molecular Probes, Leiden, The Netherlands.

| Antibody | Catalogue\(^a\) | Species | Dilution | Secondary Antibody | Visualisation |
|----------|----------------|---------|----------|--------------------|--------------|
| BrdU\(^{1}\) | ab6326 | Rat     | 1:500    | GARat-b\(^{a}\), GARat-594\(^{4}\) | Str-488\(^{1}\) |
| CC3\(^{2}\) | Asp175 | Rabbit | 1:500    | GAR-b\(^{3}\) | Str-488\(^{1}\) |
| COUPTFII\(^{2}\) | PP-H7147-00 | Mouse | 1:200 | GAM-568\(^{1}\) | N/A |
| \(\gamma\)H2AX (phospho S139)\(^{3}\) | ab22551 | Mouse | 1:200 | GAM-488\(^{4}\) | N/A |
| Mvh\(^{1}\) | ab27591 | Mouse | 1:100 | GAM-568\(^{1}\) | N/A |
| PLZF\(^{1}\) | ab189489 | Rabbit | 1:3000 | GAR-488\(^{4}\) | N/A |
| Sox9\(^{4}\) | AB5535 | Rabbit | 1:500 | GARat-594\(^{4}\) | N/A |

**Table 2.** Double immunohistochemistry protocol. Abbreviations: GAM-488: Alexafluor Goat anti-mouse IgG 488 nm. GAM-568: Alexafluor Goat anti-mouse IgG\(_5\) 568 nm. GARat-594: Alexafluor Goat anti-rat IgG\(_5\) 594 nm. GARE88: Alexafluor Goat anti-rabbit IgG 488 nm. GAR-b: Goat anti-rabbit biotinylated. GARat-b: Goat anti-rat biotinylated. Str-488: Streptavidin 488. Companies: 1Cell Signalling Technology, USA; 2R&D systems, USA; 3Abcam, UK; 4Millipore, UK; 5Vector Laboratories, USA; 6Invitrogen, UK; 7Life Technologies, UK; 8Molecular Probes, Leiden, The Netherlands.

| Antigen 1 | Dilution | Secondary Antibody | Visualisation | Antigen 2 | Dilution | Secondary Antibody | Visualisation |
|-----------|----------|--------------------|--------------|-----------|----------|--------------------|--------------|
| CC3\(^{2}\) | 1:500    | GAR-b\(^{3}\) | Str-488\(^{4}\) | Mvh\(^{3}\) | 1:100    | GAM-568\(^{4}\) | N/A |
| COUPTFII\(^{2}\) | 1:200 | GAM-568\(^{4}\) | N/A | CC3\(^{2}\) | 1:500 | GAR-b\(^{3}\) | Str-488\(^{4}\) |
| Mvh\(^{1}\) | 1:100    | GAM-568\(^{1}\) | N/A | BrdU\(^{1}\) | 1:500 | GARat-b\(^{3}\) | Str-488\(^{4}\) |
| Sox9\(^{4}\) | 1:500 | GARat-594\(^{4}\) | N/A | BrdU\(^{1}\) | 1:500 | GARat-594\(^{4}\) | Str-488\(^{4}\) |
References

1. Anderson, R. A. et al. Cancer treatment and gonadal function: experimental and established strategies for fertility preservation in children and young adults. *The Lancet Diabetes & Endocrinology* 3, 556–567 (2015).

2. Sharpe, R. M. et al. Role of the neonatal period of pituitary-testicular activity in germ cell proliferation and differentiation in the primate testis. *Hum Reprod* 18, 2110–2117 (2003).

3. Sharpe, R. M., McKinnell, C., Kivlin, C. & Fisher, J. S. Proliferation and functional maturation of Sertoli cells, and their relevance to disorders of testis function in adulthood. *Reproduction* 125, 769–784 (2003).

4. Chemes, H. E. Infancy is not a quiescent period of testicular development. *International Journal of Andrology* 24, 2–7 (2001).

5. Mitchell, R. T., O’Hara, L. & Smith, I. B. Gonadotropin and Steroid Hormone Control of Spermatogonial Differentiation. in *The Biology of Mammalian Spermatogonia*. (eds. J. Oatley & M. Griswold) (In press; 2017).

6. Rokke, S. A. & Crawford, J. D. The relationship of gonadal activity and chemotherapy-induced gonadal damage. *JAMA* 259, 2123–2125 (1988).

7. Wallace, W. H. B., Anderson, R. A. & Irvine, D. S. Fertility preservation for young patients with cancer: who is at risk and what can be offered? *The Lancet Oncology* 6, 209–218 (2005).

8. Kelner, C. J. H. et al. Testicular changes during infantile ‘quiescence’ in the marmoset and their gonadotrophin dependence: a model for investigating susceptibility of the prepubertal human testis to cancer therapy? *Human Reproduction* 17, 1367–1378 (2002).

9. Chow, E. J. et al. Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. *Hum Reprod Oncol* 17, 567–576 (2016).

10. Hall, A. G. & Tilby, M. J. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. *Blood Reviews* 6, 163–173 (1992).

11. Green, D. M. et al. Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. *Hum Reprod* 15, 1215–1223 (2014).

12. Dasari, S. & Bernard Tchounwou, P. Cisplatin in cancer therapy: Molecular mechanisms of action. *European Journal of Pharmacology* 740, 364–378 (2014).

13. Gewirtz, D. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. *Biochemical Pharmacology* 57, 727–741 (1999).

14. Meistrich, M. L. Effects of chemotherapy and radiotherapy on spermatogenesis in humans. *Fertil Steril* 100, 1180–1186 (2013).

15. Luque, F., Smith, R., Nash, S., Mitchell, R. T. & Spears, N. Immunoelectron metabolic SIN3B results in germ cell loss in the testis but not in the ovary of prepubertal mice. *Mol Hum Reprod* 22, 745–755 (2016).

16. Ehmcke, J., Wistuba, J. & Schlatt, S. Spermatogonial stem cells: questions, models and perspectives. *Hum Reprod Update* 12, 275–282 (2006).

17. Kilcoyne, K. R. et al. Fetal programming of adult Leydig cell function by androgenic effects on stem/progenitor cells. *Proceedings of the National Academy of Sciences* 111, E1924–E1932 (2014).

18. Hamer, G. et al. DNA double-strand breaks and gamma-H2AX signaling in the testis. *Biol Reprod* 68, 628–634 (2003).

19. Rube, C. E., Zhang, S., Miebach, N., Fricke, A. & Rube, C. Protecting the heritable genome: DNA damage response mechanisms in spermatogonial stem cells. *DNA Repair (Amst)* 10, 159–168 (2011).

20. Lu, M., Hales, B. F. & Robaire, B. Effects of four chemotherapeutic agents, bleomycin, Etoposide, Cisplatin, and cyclophosphamide, on DNA damage and telomeres in a mouse spermatogonial cell line. *Biol Reprod* 92, 1–7 (2014).

21. Romerius, P. et al. High risk of azoospermia in men treated for childhood cancer. *Int J Androl* 34, 69–76 (2011).

22. Struck, R. F. et al. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. *Cancer Res* 47, 2723–2726 (1987).

23. Tasso, M. J. et al. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. *Cancer Chemother Pharmacol* 30, 207–211 (1992).

24. Crom, W. R. et al. Cisplatin disposition in children and adolescents with cancer. *Cancer Chemother Pharmacol* 6, 95–99 (1981).

25. Uren, S. & Lokic, F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. *Br J Clin Pharmacol* 57, 756–763 (2004).

26. Greene, R. F., Collins, J. M., Jenkins, J. F., Speyer, J. L. & Myers, C. E. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. *Cancer Res* 43, 3417–3421 (1983).

27. Cai, L., Hales, B. F. & Robaire, B. Induction of apoptosis in the germ cells of adult male rats after exposure to cyclophosphamide. *Biol Reprod* 56, 1490–1497 (1997).

28. Suter, L., Bobadilla, M., Koch, E. & Bechter, R. Flow cytometric evaluation of the effects of doxorubicin on rat spermatogenesis. *Reprod Toxicol* 11, 521–531 (1997).

29. Zhang, X., Yamamoto, N., Soramoto, S. & Takenaka, I. Cisplatin-induced germ cell apoptosis in mouse testes. *Arch Androl* 46, 43–49 (2001).

30. Seaman, F., Sawhney, P., Giammona, C. J. & Richburg, J. H. Cisplatin-induced pulse of germ cell apoptosis precedes long-term elevated apoptotic rates in C57/BL6 mouse testis. *Aptosis* 8, 101–108 (2003).

31. Drumond, A. L. et al. Effects of multiple doses of cyclophosphamide on mouse testes: accessing the germ cells lost, and the functional damage of stem cells. *Reprod Toxicol* 32, 395–406 (2011).

32. Mitchell, R. T., Saunders, P. T., Sharpe, R. M., Kelnar, C. I. & Wallace, W. H. Male fertility and strategies for fertility preservation following childhood cancer treatment. *Endocr Dev* 15, 101–134 (2009).

33. Picton, H. M. et al. A European perspective on testicular tissue cryopreservation for fertility preservation in prepubertal and adolescent boys and girls. *Hum Reprod* 30, 2463–2475 (2015).

34. Nurmio, M. et al. Effect of childhood acute lymphoblastic leukemia therapy on spermatogonia populations and future fertility. *J Clin Endocrinol Metab* 94, 2119–2122 (2009).

35. Jahnukainen, K. et al. Semen quality and fertility in adult long-term survivors of childhood acute lymphoblastic leukemia. *Fertil Steril* 96, 837–842 (2011).

36. Velez de la Calle, J. F. et al. Reproductive effects of the anticancer drug cyclophosphamide in male rats at different ages. *Arch Androl* 22, 251–263 (1989).

37. Nayak, G. et al. Sperm abnormalities induced by pre-pubertal exposure to cyclophosphamide are effectively mitigated by Moringa oleifera leaf extract. *Andrologie* 48, 125–136 (2016).

38. Hou, M. et al. Doxorubicin induces apoptosis in germ line stem cells in the immature rat testis and amifostine cannot protect against this cytotoxicity. *Cancer Res* 65, 9999–10005 (2005).

39. Brilliante, O., Okada, F. K., Sasso-Cerri, E., Stumpf, T. & Miraglia, S. M. Late morfounfunctional alterations of the Sertoli cell caused by doxorubicin administered to prepubertal rats. *Reprod Biol Endocrinol* 10, 79 (2012).

40. Nurmio, M. et al. Functional in vitro model to examine cancer therapy cytotoxicity in maturing rat testis. *Reprod Toxicol* 27, 28–34 (2009).

41. McKinnell, C. et al. Perinatal germ cell development and differentiation in the male marmoset (Callithrix jacchus): similarities with the human and differences from the rat. *Hum Reprod* 28, 886–896 (2013).

42. Mah, L. J., El-Osta, A. & Karagiannis, T. C. gammaH2AX: a sensitive molecular marker of DNA damage and repair. *Leukemia* 24, 679–686 (2010).

43. Blanco-Rodriguez, J. gammaH2AX marks the main events of the spermatogenic process. *Micros Res Tech* 72, 823–832 (2009).
44. Dirks-Naylor, A. J. The role of autophagy in doxorubicin-induced cardiotoxicity. Life Sci (2013).
45. Rebbaa, A., Zheng, X., Chou, P. M. & Mirkin, B. L. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene 22, 2805–2811 (2003).
46. Eom, Y. W. et al. Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 24, 4765–4777 (2005).
47. Zohni, K., Xiang, X., Tan, S. L., Chan, P. & Nagano, M. C. The efficiency of male fertility restoration is dependent on the recovery kinetics of spermatogonial stem cells after cytotoxic treatment with busulfan in mice. Hum Reprod 27, 44–53 (2012).
48. Akbarinejad, V., Tajik, P., Movahedin, M. & Youssefi, R. Effect of Removal of Spermatogonial Stem Cells (SSCs) from In Vitro Culture on Gene Expression of Niche Factors in Bovine. Avicenna J Med Biotechnol 8, 133–138 (2016).
49. Sawhney, P., Giammona, C. J., Meistrich, M. L. & Richburg, J. H. Cisplatin-induced long-term failure of spermatogenesis in adult C57/Bl/6j mice. J Androl 26, 136–145 (2005).
50. Jahnukainen, K., Ehmcke, J., Nurmio, M. & Schlatt, S. Irradiation causes acute and long-term spermatogonial depletion in cultured and xenotransplanted testicular tissue from juvenile nonhuman primates. Endocrinology 148, 5541–5548 (2007).
51. de Rooij, D. G. et al. Long-term effects of irradiation before adulthood on reproductive function in the male rhesus monkey. Biol Reprod 66, 486–494 (2002).
52. Trondle, I. et al. Irradiation affects germ and somatic cells in prepubertal monkey testis xenografts. Mol Hum Reprod 23, 141–154 (2017).
53. Madden, J. A., Hoyer, P. B., Devine, P. I. & Keating, A. F. Involvement of a volatile metabolite during phosphoramide mustard-induced ovotoxicity. Toxicol Appl Pharmacol 277, 1–7 (2014).

Acknowledgements

We thank Anisha Kubasik for help on image acquisition and advice on IHC quantification, Crispin Jordan for statistical advice and Sophie Nash for work in Supplementary figure S2 showing correlation of IHC images between automated measures of expression and manual cell counts. Work supported by Medical Research Grant (MRC) grant G1002118 and Children with Cancer UK grant 15–198. RTM is supported by a Wellcome Trust Intermediate Clinical Fellowship (Grant Number: 098522).

Author Contributions

E.S. and F.L. participated in the design of the study, led experiments, prepared figures and helped draft the manuscript. S.R. and B.N. participated in cultures and analyses and helped prepare figures. R.A.A. participated in design of the study and helped draft the manuscript. R.T.M. conceived and designed the study and helped draft the manuscript. N.S. conceived, designed and coordinated the study and wrote the manuscript. All authors read and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-19761-9.

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018